Studio su REGN5668 somministrato in combinazione con cemiplimab o REGN4018 in donne adulte con carcinoma ovarico ricorrente
Studio di fase 1/2 su REGN5668 (MUC16xCD28, un bispecifico costimolatorio) somministrato in combinazione con Cemiplimab o REGN4018 (MUC16xCD3)
This study is researching an investigational drug called REGN5668 :
- alone or,
- combined with cemiplimab (also known as REGN2810) or,
- combined with both cemiplimab and fianlimab (also known as REGN3767), or
- combined with ubamatamab (also known as REGN4018), with or without sarilumab.
The main purposes of this study are to:
- Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
- Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus
This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.
The study is looking at several other research questions, including:
- Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
- How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
- To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Clinical Trials Administrator
- Numero di telefono: 844-734-6643
- Email: clinicaltrials@regeneron.com
Luoghi di studio
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgio, 3000
- Reclutamento
- Universitair Ziekenhuis Leuven
-
-
-
-
-
São Paulo, Brasile, 01509-010
- Reclutamento
- AC Camargo Cancer Center, Fundacao Antonio Prudente
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasile, 90619-900
- Reclutamento
- Centro de Pesquisa em Oncologia PUCRS
-
-
São Paulo
-
Barretos, São Paulo, Brasile, 14784-400
- Reclutamento
- Fundacao Pio XII - Hospital de Cancer de Barretos
-
Sorocaba, São Paulo, Brasile, 18065-100
- Reclutamento
- Unimed Sorocaba
-
-
-
-
-
Villejuif, Francia, 94805
- Reclutamento
- Institut Gustave Roussy
-
-
Auvergne-Rhône
-
Pierre-Bénite, Auvergne-Rhône, Francia, 69310
- Reclutamento
- Hopital Lyon Sud
-
-
Bourgogne-Franche-Comté
-
Dijon, Bourgogne-Franche-Comté, Francia, 21000
- Reclutamento
- Centre Georges Francois Leclerc
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, Francia, 33076
- Reclutamento
- Institut Bergonie
-
-
Normandy
-
Caen, Normandy, Francia, 14076
- Reclutamento
- Centre Francois Baclesse (CFB)
-
-
-
-
-
Girona, Spagna, 17007
- Reclutamento
- Institut Catala dOncologia Girona
-
Madrid, Spagna, 28040
- Reclutamento
- Hospital Universitario Fundacion Jimenez
-
Madrid, Spagna, 28040
- Reclutamento
- Ciudad Universitaria
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spagna, 15706
- Reclutamento
- Hospital Clinico Universitario Santiago de Compostela
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Reclutamento
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Stati Uniti, 92618
- Reclutamento
- The City of Hope Orange County Lennar Foundation Cancer Center
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Chao Family Comprehensive Cancer Center
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Completato
- H. Lee Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital
-
Boston, Massachusetts, Stati Uniti, 02215
- Reclutamento
- Dana Farber Cancer Institute Brookline Avenue
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Karmanos Cancer Institute
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University Wexner Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Perelman School of Medicine at the University of Pennsylvania
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Seattle Cancer Care Alliance at South Lake Union - G3630
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
- Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
- Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
- Has adequate organ and bone marrow function as defined in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Has a life expectancy of at least 3 months
- Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol
Key Exclusion Criteria:
- Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
- Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
- Prior treatment with a Mucin 16 (MUC16)-targeted therapy
- Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
- Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
- Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
- Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
- Has history of clinically significant cardiovascular disease as defined in the protocol
- Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Module 1
REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab |
Administer per the protocol
Altri nomi:
Administer per the protocol
Altri nomi:
Administer per the protocol |
|
Sperimentale: Module 2
REGN5668 and ubamatamab |
Administer per the protocol
Altri nomi:
Administer per the protocol
Altri nomi:
Administer per the protocol
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence of Dose Limiting Toxicities (DLT)
Lasso di tempo: 42 days
|
Dose escalation phase, Module 1 |
42 days
|
|
Incidence of DLTs
Lasso di tempo: 21 days post combination administration
|
Dose escalation phase, Module 2 |
21 days post combination administration
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of Serious Adverse Events (SAEs)
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of deaths
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase Secondary: Dose expansion phase |
Through study completion, up to 5 years
|
|
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose escalation phase |
Through study completion, up to 5 years
|
|
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Lasso di tempo: Through study completion, up to 5 years
|
Primary: Dose expansion phase |
Through study completion, up to 5 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
ORR based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation phase |
Through study completion, up to 5 years
|
|
Best Overall Response (BOR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Duration Of Response (DOR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Disease Control Rate (DCR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Progression-Free Survival (PFS) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against REGN5668
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against ubamatamab
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against cemiplimab
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
|
Presence or absence of anti-drug antibodies against fianlimab
Lasso di tempo: Through study completion, up to 5 years
|
Dose escalation and expansion phases |
Through study completion, up to 5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Attributi della malattia
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie delle ghiandole endocrine
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Neoplasie uterine
- Malattie delle tube di Falloppio
- Condizioni patologiche, segni e sintomi
- Ricorrenza
- Neoplasie ovariche
- Neoplasie endometriali
- Neoplasie delle tube di Falloppio
- Cemiplimab
- Sarilumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- R5668-ONC-1938
- 2022-501904-83-00 (Ctis)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Periodo di condivisione IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Criteri di accesso alla condivisione IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .